1-20 of 22
Malcolm A. Smith
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract C095: The menin inhibitor VTP-50469 enhances the in vivo efficacy of established drugs against preclinical models of aggressive infant MLL-r acute lymphoblastic leukemia

Free
Richard B Lock, Kathryn Evans, Sophia Gawan-Taylor, Ben Watts, Timothy Stearns, Eric J Earley, Emily L Jocoy, Carol J Bult, Beverly A Teicher, Gerard M McGeehan, Malcolm A Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): C095.
https://doi.org/10.1158/1535-7163.TARG-23-C095
Published: 01 December 2023
View articletitled, Abstract C095: The menin inhibitor VTP-50469 enhances the in vivo efficacy of established drugs against preclinical models of aggressive infant MLL-r acute lymphoblastic leukemia
Journal Articles

Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium

Available to Purchase
Pooja Hingorani, Wendong Zhang, Zhongting Zhang, Zhaohui Xu, Wei-Lien Wang, Michael E. Roth, Yifei Wang, Jonathan B. Gill, Douglas J. Harrison, Beverly A. Teicher, Stephen W. Erickson, Gregory Gatto, Edward A. Kolb, Malcolm A. Smith, Raushan T. Kurmasheva, Peter J. Houghton, Richard Gorlick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (8): 1318–1325.
https://doi.org/10.1158/1535-7163.MCT-21-0758
Published: 02 August 2022
View articletitled, Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium
Open the PDF for Trastuzumab Deruxtecan, Antibody–Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium in another window
Journal Articles

Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma

Open Access
Yifei Wang, Xiangjun Tian, Wendong Zhang, Zhongting Zhang, Rossana Lazcano, Pooja Hingorani, Michael E. Roth, Jonathan D. Gill, Douglas J. Harrison, Zhaohui Xu, Sylvester Jusu, Sankaranarayanan Kannan, Jing Wang, Alexander J. Lazar, Eric J. Earley, Stephen W. Erickson, Tara Gelb, Philip Huxley, Johanna Lahdenranta, Gemma Mudd, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith, Edward A. Kolb, Richard Gorlick
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 903–913.
https://doi.org/10.1158/1535-7163.MCT-21-0836
Published: 01 June 2022
View articletitled, Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma
Open the PDF for Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma in another window
Includes: Supplementary data
Journal Articles

International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer

Open Access
Gilles Vassal, Peter J. Houghton, Stefan M. Pfister, Malcolm A. Smith, Huib N. Caron, Xiao-Nan Li, David J. Shields, Olaf Witt, Jan J. Molenaar, Sara Colombetti, Julia Schüler, Lou F. Stancato
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (8): 1462–1468.
https://doi.org/10.1158/1535-7163.MCT-20-0394
Published: 01 August 2021
View articletitled, International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer
Open the PDF for International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer in another window
Includes: Supplementary data
Journal Articles

ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium

Free
Pooja Hingorani, Michael E. Roth, Yifei Wang, Wendong Zhang, Jonathan B. Gill, Douglas J. Harrison, Beverly Teicher, Stephen Erickson, Gregory Gatto, Malcolm A. Smith, Edward A. Kolb, Richard Gorlick
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (3): 535–540.
https://doi.org/10.1158/1535-7163.MCT-20-0406
Published: 02 March 2021
View articletitled, ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium
Open the PDF for ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium in another window
Includes: Supplementary data
Journal Articles

Abstract C004: The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia

Free
Richard B Lock, Kathryn Evans, Connor D Jones, Narimanne El-Zein, Stephen W Erickson, Sarah Beaussant-Cohen, E. Lynne Kelley, Beverly A Teicher, Malcolm A Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C004.
https://doi.org/10.1158/1535-7163.TARG-19-C004
Published: 01 December 2019
View articletitled, Abstract C004: The CXCR4 inhibitor X4-136 enhances the in vivo efficacy of established drugs against preclinical models of aggressive pediatric acute lymphoblastic leukemia
Journal Articles

Abstract LB-B04: A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma

Free
Amber K. Weiner, Alexander B. Radaoui, Matthew Tsang, Dan Martinez, Simone Sidoli, Karina L. Conkrite, Alberto Delaidelli, Jo Lynne Rokita, Maria V. Lane, Zalman Vaksman, Komal S. Rathi, Pichai Raman, Jennifer Pogoriler, Tricia Bhatti, Bruce Pawel, Beverly Teicher, Stephen W. Erickson, Poul Sorensen, Yael P. Mosse, Kateryna Krytska, Francesca Zammarchi, Patrick H. van Berkel, Malcolm A. Smith, Benjamin A. Garcia, John M. Maris, Sharon J. Diskin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): LB-B04.
https://doi.org/10.1158/1535-7163.TARG-19-LB-B04
Published: 01 December 2019
View articletitled, Abstract LB-B04: A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma
Journal Articles

Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)

Free
Raushan Kurmasheva, E. Anders Kolb, Malcolm A. Smith, Beverly A. Teicher, Stephen W. Erickson, John M. Maris, Yael P. Mosse, Kateryna Krytska, David Groff, Matthew Tang, Yifei Wang, Brad St. Croix, Richard Gorlick, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): C003.
https://doi.org/10.1158/1535-7163.TARG-19-C003
Published: 01 December 2019
View articletitled, Abstract C003: Initial testing of m276-PBD CD276 antibody-drug conjugate in preclinical models of pediatric cancers by the Pediatric Preclinical Testing Consortium (PPTC)
Journal Articles

Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study

Free
Richard B. Lock, Kathryn Evans, Raymond Yung, Tara Pritchard, Beverly A. Teicher, JianXin Duan, Yuelong Guo, Stephen W. Erickson, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B16.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B16
Published: 01 January 2018
View articletitled, Abstract LB-B16: The AKR1C3-Activated Prodrug OBI-3424 Exerts Profound In Vivo Efficacy Against Preclinical Models of T-Cell Acute Lymphoblastic Leukemia (T-ALL); a Pediatric Preclinical Testing Consortium Study
Journal Articles

Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan

Free
Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlick, E. Anders Kolb, Yael P. Mosse, Stephen W. Erickson, Yuelong Guo, Beverly A. Teicher, Malcolm A. Smith, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B15.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B15
Published: 01 January 2018
View articletitled, Abstract LB-B15: Pediatric Preclinical Testing Consortium evaluation of the AZD1775 as a single agent and in combination with irinotecan
Journal Articles

Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)

Free
Beverly A. Teicher, Richard B. Lock, Jerry M. Collins, Richard Gorlick, E. Anders Kolb, Peter J. Houghton, Raushan T. Kurmasheva, Xiao-Nan Li, Stephen W. Erickson, Yuelong Guo, Kathryn Evans, Lin Qi, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B12.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B12
Published: 01 January 2018
View articletitled, Abstract LB-B12: Pediatric Preclinical Testing Consortium evaluation of 4’-thio-2’-deoxycytidine (TdCyd) and 5-aza-4’-thio-2’-deoxycytidine (Aza-TdCyd)
Journal Articles

Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602

Free
Kateryna Krytska, Kathryn Evans, Tara Pritchard, Matthew Tsang, Raymond Yung, Yael P. Mosse, Stephen W. Erickson, Yuelong Guo, Erkan Baloglu, Yosef Landesman, Kyle A. Jensen, William Senapedis, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B14.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B14
Published: 01 January 2018
View articletitled, Abstract LB-B14: Pediatric Preclinical Testing Consortium evaluation of the second-generation selective inhibitor of nuclear export (SINE) compound KPT-8602
Journal Articles

Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib

Free
Kristina A. Cole, Peter J. Houghton, Raushan T. Kurmasheva, Richard Gorlick, E. Anders Kolb, Min Kang, C. Patrick Reynolds, Xiao-Nan Li, Holly Lindsay, Stephen W. Erickson, Yuelong Guo, Beverly A. Teicher, Malcolm A. Smith, John M. Maris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): LB-B13.
https://doi.org/10.1158/1535-7163.TARG-17-LB-B13
Published: 01 January 2018
View articletitled, Abstract LB-B13: Pediatric Preclinical Testing Consortium evaluation of the CHK1 inhibitor prexasertib
Journal Articles

Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia

Free
Santi Suryani, Lauryn S. Bracken, Richard C. Harvey, Keith C.S. Sia, Hernan Carol, I-Ming Chen, Kathryn Evans, Philipp A. Dietrich, Kathryn G. Roberts, Raushan T. Kurmasheva, Catherine A. Billups, Charles G. Mullighan, Cheryl L. Willman, Mignon L. Loh, Stephen P. Hunger, Peter J. Houghton, Malcolm A. Smith, Richard B. Lock
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (2): 364–374.
https://doi.org/10.1158/1535-7163.MCT-14-0647
Published: 09 February 2015
View articletitled, Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia
Open the PDF for Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Letter

Free
Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (3): 763.
https://doi.org/10.1158/1535-7163.MCT-13-0968
Published: 09 March 2014
View articletitled, Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Letter
Open the PDF for Sorafenib Inhibits ABCG2 and Overcomes Irinotecan Resistance—Letter in another window
Journal Articles

Abstract C107: The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

Free
Richard B. Lock, Hernan Carol, Barbara Szymanska, Ingrid Boehm, Kathryn Evans, Peter J. Houghton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C107.
https://doi.org/10.1158/1535-7163.TARG-11-C107
Published: 12 November 2011
View articletitled, Abstract C107: The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse post induction therapy in preclinical models of pediatric acute lymphoblastic leukemia.
Journal Articles

Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).

Free
C. Patrick Reynolds, Min H. Kang, Hernan Carol, Richard B. Lock, Richard Gorlick, E. Anders Kolb, Denise Alexander, Raushan T. Kurmasheva, Stephen T. Keir, John M. Maris, Jianrong Wu, Peter J. Houghton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C106.
https://doi.org/10.1158/1535-7163.TARG-11-C106
Published: 12 November 2011
View articletitled, Abstract C106: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the PI3K inhibitor XL147 (SAR245408).
Journal Articles

Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.

Free
Malcolm A. Smith, Min H. Kang, Christopher Patrick Reynolds, Richard B. Lock, Hernan Carol, Richard Gorlick, E. Anders Kolb, John M. Maris, Stephen T. Keir, Catherine A. Billups, Raushan T. Kurmasheva, Peter J. Houghton
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C103.
https://doi.org/10.1158/1535-7163.TARG-11-C103
Published: 12 November 2011
View articletitled, Abstract C103: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of the p53-MDM2 antagonist RG7112: Early evidence for high activity against MLL-rearranged leukemias.
Journal Articles

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

Free
Peter J. Houghton, Christopher L. Morton, Richard Gorlick, Richard B. Lock, Hernan Carol, C. Patrick Reynolds, Min H. Kang, John M. Maris, Stephen T. Keir, E. Anders Kolb, Jianrong Wu, Amy W. Wozniak, Catherine A. Billups, Larry Rubinstein, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 101–112.
https://doi.org/10.1158/1535-7163.MCT-09-0952
Published: 12 January 2010
View articletitled, Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program
Open the PDF for Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program in another window
Includes: Supplementary data
Journal Articles

Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase

Free
Peter J. Houghton, John M. Maris, Josh Courtright, Henry S. Friedman, Stephen T. Keir, Richard B. Lock, Hernan Carol, E. Anders Kolb, Richard Gorlick, Min Kang, C. Patrick Reynolds, Christopher L. Morton, Malcolm A. Smith
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C57.
https://doi.org/10.1158/1535-7163.TARG-09-C57
Published: 10 December 2009
View articletitled, Abstract C57: Pediatric Preclinical Testing Program (PPTP) Stage 1 evaluation of AZD8055 an inhibitor of mTOR Kinase